- GlobeNewswire•2 days agoCellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
BEVERLY, Mass., Dec. 07, 2016-- Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, ...
- Capital Cube•10 days ago
Categories: Yahoo Finance Get free summary analysis Cellceutix Corp. reports financial results for the quarter ended September 30, 2016. Analysis Summary numbers: Revenues of USD 0 million, Net Earnings of USD -3.03 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. CTIX-US‘s earnings and ... Read more (Read more...)
- GlobeNewswire•25 days ago
Enrollment Underway in Phase 2 b Study of Prurisol for Moderate to Severe Plaque Psoriasis. Positive Initial Data Reported in Phase 2 a Proof of Concept Open-Label Study of Brilacidin for Inflammatory ...
CTIX : Summary for CELLCEUTIX CORP COM STK USD0.00 - Yahoo Finance
Cellceutix Corporation (CTIX)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||1.15 - 1.23|
|52 Week Range||0.91 - 1.92|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-10.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|